Demetrix, a biotechnology company focused on the production of cannabinoids, has secured $50 million in Series A funding. The round was led by Tuatara Capital with participation from existing investor Horizons Ventures. Horizons Ventures previously led Demetrix’s $11 million Series Seed round.
"Over the last decade, the supply chain for this rapidly-developing global market has largely relied on traditional plant cultivation and extraction operations to produce high purity THC and CBD," the team with the company explains. "However, the majority of cannabinoids in the plants are in very low concentrations and cannot be economically produced via plant extraction. We are working to solve this problem by using baker’s yeast to consistently produce large volumes of any cannabinoid at high quality, high purity, and lower cost. We intend to use our Series A funding to scale its operations and commercialize the first of more than 100 unique cannabinoids.
“Demetrix’s mission is to help the world benefit from nature’s rarest ingredients, and we’re excited to partner with world-class investors like Tuatara Capital and Horizons Ventures to help global pharmaceutical, supplement, and consumer product companies deliver innovative products using cannabinoids,” said Demetrix CEO Jeff Ubersax. “We’ve assembled a team of industry veterans, built a scalable technology platform, and are working with global regulatory organizations to quickly commercialize.”
Demetrix employs an industry-leading fermentation technology that accelerates the production of cannabinoids. The company has improved production by several orders of magnitude over what was reported in the February 27, 2019 issue of the journal Nature that featured the technology.
“Tuatara Capital partners with industry-defining companies that are shaping the future of the legal cannabis industry, and we are excited to lead this investment in Demetrix. The team at Demetrix has a proven track record of commercializing rare ingredients at scale and have extraordinary expertise with both biological engineering and research and development around cannabinoids. The ability to consistently produce high purity, single cannabinoids in a process that easily scales to meet demand is an important factor for this emerging industry,” said Marc Riiska, Partner at Tuatara Capital.
“Horizons Ventures shares Demetrix’s passion for unlocking the potential of natural ingredients for customers around the world via its cutting-edge synthetic biology work, a field that we truly believe will bring a seismic shift to the world. Cannabinoids hold tremendous promise for improving human health, and Demetrix is uniquely positioned to bring these compounds to market in a cost-efficient way. We’re excited and proud to be part of this journey,” said Patrick Zhang at Horizons Ventures.
For more information:
Demtrix
demetrixbio.com